The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Major adverse cardiac events (MACE) with immune checkpoint inhibitor (ICI)-based therapies for cancer: A pooled analysis of investigational clinical trials sponsored by the National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP) in the United States and Canada.
 
Abdul Rafeh Naqash
No Relationships to Disclose
 
Melissa Moey
No Relationships to Disclose
 
Xiao-Wei Cherie Tan
No Relationships to Disclose
 
Mehak Masood Laharwal
No Relationships to Disclose
 
Vanessa Hill
No Relationships to Disclose
 
Nagabhishek Moka
No Relationships to Disclose
 
Shanda Finnigan
No Relationships to Disclose
 
James H. Murray
No Relationships to Disclose
 
Douglas Buckner Johnson
Consulting or Advisory Role - Bristol-Myers Squibb; Catalyst Pharmaceuticals; Iovance Biotherapeutics; Janssen; Merck; Mosaic ImmunoEngineering; Novartis; Oncosec; Pfizer; Targovax
Research Funding - Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy
 
Javid J. Moslehi
Consulting or Advisory Role - AstraZeneca/MedImmune; BMS; Boehringer Ingelheim; Deciphera; Mallinckrodt; Myovant Sciences; Novartis; Pfizer; Pharmacyclics; Star Therapeutics
 
Elad Sharon
No Relationships to Disclose